Results 81 to 90 of about 2,201,777 (199)

Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis

MedComm
Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in lung adenocarcinoma (LUAD), but the underlying mechanisms are still not fully understood.
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu   +5 more
doaj   +1 more source

Factors Associated With Long‐Term Survivors With Epidermal Growth Factor Receptor Positive Non‐Small Cell Lung Cancer Treated With First or Second‐Generation Tyrosine Kinase Inhibitors: A Canadian Multi‐Center Cohort

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In a multi‐center Canadian cohort of 577 patients with advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer treated with first/second‐generation TKIs, Asian ancestry and female sex predicted longer survival, while the L858R mutation predicted shorter survival.
Heather Halperin, Amanda J. W. Gibson, Ali Hussein, Mike Sung, Pascale Tomasini, Michelle Dean, Jennifer H. Law, Cheryl Ho, Vishal Navani, Natasha B. Leighl, Desiree Hao   +10 more
wiley   +1 more source

Selpercatinib Overcomes CCDC6-RET–Mediated Resistance to Osimertinib [PDF]

Journal of Thoracic Oncology, 2021
Misty D, Shields, J Kevin, Hicks, Theresa A, Boyle, Eric B, Haura, Benjamin C, Creelan   +4 more
openaire   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Comparison and Analysis of the Drug‐Resistance Mechanism of Osimertinib‐ and Almonertinib‐Resistant Cell Lines

Analytical Cellular Pathology
Background: Non–small‐cell lung cancer remains the leading cause of cancer‐related deaths globally, and epidermal growth factor receptor mutations have been identified as crucial drivers of the disease. Encouragingly, epidermal growth factor receptor tyrosine kinase inhibitors have demonstrated promising ...
Chuangjie Zheng, Yingfang Ren, Ke Wang, Xinrong Chen, Jiahao Tao, Cuifen Zhang, Zeyu Liu, Lingling Sun, Linzhu Zhai   +8 more
openaire   +3 more sources

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

Cancer Science, EarlyView.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao, Yuqiang Liu, Mingxuan Xie, Zhiming Ye, Hong Huang, Maojin Yao, Feng Zhou, Jianzhu Zhao, Jun Tang   +8 more
wiley   +1 more source

Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies

Cancer Science, EarlyView.
Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang, Junyi Xiong, Li Ying, Yanyang Zeng, Ziqiang Ouyang, Mei Liu, Meihua Li   +6 more
wiley   +1 more source

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors [PDF]

, 2017
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous ...
Marcin Skrzypski, Amelia Szymanowska-Narloch, Rafał Dziadziuszko   +2 more
core   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source